Background Colorectal adenocarcinoma is the third most common cancer worldwide and a
leading cause of cancer-related death. The recent emergence of diverse immunotherapeutic …

Immunologic profiling of colorectal cancer (CRC) may help to predict the tumors metastatic
potential and patients with an aggressive tumor, although not yet metastasized at time of …

Immune checkpoint inhibition is an effective anti-cancer therapeutic approach but has
shown limited efficacy in treating colorectal cancer (CRC) patients. Importantly, immune …

Tumor-infiltrating immune cells are heterogeneous and consist of characteristic
compartments, including T helper (Th) 1 and regulatory T (Treg) cells that exhibit distinctive …

Colorectal cancer (CRC) has one of the highest cancer incidences and mortality rates. In
stage III, postoperative chemotherapy benefits< 20% of patients, while more than 50% will …

Background: Cancer patients often display dysfunctional antitumor T-cell responses.
Because noteworthy benefits of immune checkpoint pathway blockade, such as …

In recent years, there has been a significant increase in the study of own and foreign human
factors favoring the development of different types of cancer, including genetic and …

Adoptive cell therapy with the use of tumor-infiltrating lymphocytes (TILs) is a very promising
immunotherapeutic approach for the treatment of patients with colorectal cancer (CRC) …

In recent years an increase of functional CD4+ CD25+ regulatory T cells (Treg cells) has
been established for patients with solid tumors, acute leukemias, and lymphomas. We have …

The immune system spontaneously responds to tumor-associated antigens in peripheral
blood of colorectal cancer (CRC) patients. Regulatory T cells (Treg) are suspected of …